Coya Therapeutics (COYA) Total Liabilities (2021 - 2026)
Coya Therapeutics (COYA) posted Total Liabilities of $4.3 million for Q1 2026, down 37.87% sequentially from $6.9 million in Q4 2025, and down 14.59% YoY from $5.0 million in Q1 2025.
Coya Therapeutics (COYA) Total Liabilities (2021 - 2026) Analysis & Trends
Coya Therapeutics has reported Total Liabilities for 6 years, with the latest figure at $4.3 million in Q1 2026.
- Quarterly Total Liabilities fell 14.59% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (down 14.59% YoY) and the FY2025 annual result came in at $6.9 million, up 45.12% from the prior year.
- Total Liabilities fell to $4.3 million in Q1 2026 per COYA's latest filing, from $6.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $16.8 million in Q4 2022 and troughed at $1.2 million in Q2 2023.
- A 5-year average of $5.1 million and a median of $4.8 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities soared 1361.98% in 2022, then tumbled 66.49% in 2023.
- Over 5 years, Total Liabilities stood at $16.8 million in 2022, then plunged by 66.49% to $5.6 million in 2023, then retreated by 15.23% to $4.8 million in 2024, then soared by 45.12% to $6.9 million in 2025, then plunged by 37.87% to $4.3 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $4.3 million, $6.9 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 10.03 Bn |
| 10 | Coya Therapeutics | 114.47 Mn | 71.27 Mn | - | 4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.03 Mn |
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2025 | 6.92 Mn |
| Sep 30, 2025 | 4.76 Mn |
| Jun 30, 2025 | 5.14 Mn |
| Mar 31, 2025 | 5.04 Mn |
| Dec 31, 2024 | 4.77 Mn |
| Sep 30, 2024 | 3.54 Mn |
| Jun 30, 2024 | 4.68 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Dec 31, 2023 | 5.63 Mn |
| Sep 30, 2023 | 1.81 Mn |
| Jun 30, 2023 | 1.22 Mn |
| Mar 31, 2023 | 1.27 Mn |
| Dec 31, 2022 | 16.79 Mn |
| Dec 31, 2021 | 1.15 Mn |